Broadwood Capital Inc. raised its holdings in shares of BioTime, Inc. (NYSEAMERICAN:BTX) by 0.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,279,254 shares of the biotechnology company’s stock after acquiring an additional 160,000 shares during the quarter. BioTime makes up 12.8% of Broadwood Capital Inc.’s investment portfolio, making the stock its 3rd largest holding. Broadwood Capital Inc. owned 22.64% of BioTime worth $77,473,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the business. Voya Investment Management LLC lifted its holdings in shares of BioTime by 38.3% during the 2nd quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 8,996 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in BioTime in the 2nd quarter worth approximately $142,000. Moors & Cabot Inc. lifted its holdings in BioTime by 25.2% in the 2nd quarter. Moors & Cabot Inc. now owns 49,630 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 10,000 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in BioTime in the 2nd quarter worth approximately $180,000. Finally, Metropolitan Life Insurance Co. NY lifted its holdings in BioTime by 14.7% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock worth $199,000 after purchasing an additional 7,411 shares during the last quarter.
Several research firms recently weighed in on BTX. BidaskClub upgraded BioTime from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Zacks Investment Research downgraded BioTime from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company. BioTime has a consensus rating of “Hold” and an average price target of $5.08.
Shares of BioTime, Inc. (BTX) traded down $0.05 during midday trading on Thursday, reaching $2.46. The company’s stock had a trading volume of 271,200 shares, compared to its average volume of 352,725. BioTime, Inc. has a 52 week low of $2.19 and a 52 week high of $3.97.
In other BioTime news, Director Broadwood Partners, L.P. purchased 2,692,307 shares of the company’s stock in a transaction on Friday, October 13th. The shares were bought at an average cost of $2.60 per share, with a total value of $6,999,998.20. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
BioTime Company Profile
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.